AstraZeneca PLC (AZN)
| Market Cap | 254.56B +11.3% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.68 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 24.37 |
| Forward PE | 15.16 |
| Dividend | $3.23 (1.98%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 143,891 |
| Open | 164.35 |
| Previous Close | 164.21 |
| Day's Range | 163.23 - 164.35 |
| 52-Week Range | 146.10 - 212.71 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 212.17 (+29.97%) |
| Earnings Date | Oct 30, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $212.17, which is an increase of 29.97% from the latest price.
News
Morning Movers: Summit Therapeutics jumps after AstraZeneca investment
Sstock futures have edged higher in early trading as technology stocks stabilize, but elevated oil prices and Treasury yields tied to ongoing Middle East tensions continue to temper risk appetite.
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
Summit Therapeutics shares surged more than 20% in pre-market trading on Tuesday after AstraZeneca agreed to invest $2 billion in the company and collaborate on a series of clinical studies involving ...
Why Is Summit Therapeutics Stock (SMMT) Soaring in Premarket Today, Sept. 29?
Summit Therapeutics ($SMMT) stock is up 22% in Tuesday’s premarket trading. The gain came after AstraZeneca ($AZN) announced a $2 billion equity investment in Summit Therapeutics and a deal to…
Summit soars after $2 billion investment from AstraZeneca for cancer therapies
Summit Therapeutics' shares rose 23% in premarket trading on Tuesday after the drugmaker said AstraZeneca would invest $2 billion in the company to test cancer treatments together.
Anthropic warns of ‘existential risks to humanity' from AI; AstraZeneca makes $2bn cancer drug tie-up – business live
Rolling coverage of the latest economic and financial news
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
HUTCHMED (China) said on Tuesday Anglo-Swedish drugmaker AstraZeneca had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in pat...
Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC
Hutchmed (HCM) “announces that AstraZeneca (AZN) has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS (savolitinib) plus TAGRISSO(R) (osimertinib) for the treatment...
Closing Bell Movers: Summit Therapeutics jumps on AstraZeneca investment
Major indices started the week on a downswing as oil prices sprang higher after President Donald Trump rejected conditions for a ceasefire presented by Iran and Treasury yields extended their…
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
Summit shares surged in after-hours trading following the news of AstraZeneca's investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.
Summit Therapeutics up 15% after AstraZeneca makes $2B equity investment
In after-hours trading, shares of Summit Therapeutics (SMMT) are up 15% to $17.85.
Summit Therapeutics, AstraZeneca enter clinical collaboration agreement
Summit (SMMT) entered into a clinical collaboration agreement with AstraZeneca (AZN) to evaluate sonesitatug vedotin in combination with ivonescimab with the intent to start studies in certain gastroi...
AstraZeneca makes $2B equity investment in Summit Therapeutics
Summit Therapeutics (SMMT) announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifical...
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company's progress towards achieving its goal of making a significant difference in th...
Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)
BOSTON & SHANGHAI--(BUSINESS WIRE)--Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004).
AstraZeneca’s sBLA for IMFINZI plus enfortumab vedotin granted Priority Review
AstraZeneca’s (AZN) supplemental Biologics License Application for IMFINZI in combination with enfortumab vedotin has been accepted and granted Priority Review in the US for the treatment of patients ...
NTHM's Index Rebalance Puts Thematic Rotation to Work
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP...
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in combination with enfortumab vedotin (EV) has been accepted and granted P...
AstraZeneca sBLA for Imfinzi combination accepted, granted Priority Review
AstraZeneca’s (AZN) supplemental Biologics License Application, or sBLA, for Imfinzi in combination with enfortumab vedotin has been accepted by the FDA and granted Priority Review in the U.S. for the...
3 Undervalued International Stocks for US Investors
The ADRs of these wide-moat companies are attractive buys today.
Polaris Rx Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service for Second Consecutive Year
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Rx, a leading provider of long-term care, specialty, and infusion pharmacy solutions, has once again been selected as the exclusive U.S. distributor for...
Novo is open to upgrading its New York listing to boost US profile, FT says
Novo (NVO) is open to upgrading its New York listing to boost its profile in the U.S., following a similar move by AstraZeneca (AZN) earlier in the year, Aanu Adeoye,…
AstraZeneca reports Trixeo approved in EU for maintenance treatment of asthma
AstraZeneca’s (AZN) fixed-dose triple-combination Trixeo Aerosphere has been approved in the European Union as a maintenance treatment for asthma in patients 12 years of age and older who are not…
European drugmakers call for faster trials, more spending to compete with US, China
European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks los...
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note
In the latest trading session, Astrazeneca (AZN) closed at $168.1, marking a +1.22% move from the previous day.